Compare LARK & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | TMCI |
|---|---|---|
| Founded | 1885 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 174.6M |
| IPO Year | N/A | 2021 |
| Metric | LARK | TMCI |
|---|---|---|
| Price | $25.64 | $2.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.96 |
| AVG Volume (30 Days) | 9.3K | ★ 970.4K |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | $64,367,999.00 | ★ $218,879,000.00 |
| Revenue This Year | N/A | $3.25 |
| Revenue Next Year | N/A | $0.99 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 12.95 | 7.90 |
| 52 Week Low | $20.99 | $2.36 |
| 52 Week High | $29.56 | $10.79 |
| Indicator | LARK | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 24.40 | 50.24 |
| Support Level | $24.85 | $2.42 |
| Resistance Level | $26.03 | $2.56 |
| Average True Range (ATR) | 0.70 | 0.17 |
| MACD | -0.40 | 0.12 |
| Stochastic Oscillator | 4.90 | 82.50 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.